You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Mitogen-Activated Protein Kinase (MEK) Inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)

Active, not recruiting
  • Neurofibromatosis 1
  • Neurofibroma Plexiform
  • Shanghai, China
  • +1 more
Jan 13, 2023

Neurofibromatosis 1, Neurofibromatosis Type 1, NF1 Trial run by the National Cancer Institute (NCI) (AZD6244)

Active, not recruiting
  • Neurofibromatosis 1
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022

Neurofibromatosis Type 1 Trial in Japan (Selumetinib)

Active, not recruiting
  • Neurofibromatosis Type 1
  • Minato-ku, Japan
  • +3 more
Jun 9, 2022

Pancreatic Ductal Adenocarcinoma Trial (combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • combination therapy with no MEKi
  • +3 more
  • (no location specified)
Nov 29, 2022

Tumor, Solid, Gastrointestinal Cancer Trial in San Francisco, Ann Arbor (Ulixertinib, Hydroxychloroquine)

Recruiting
  • Tumor, Solid
  • Gastrointestinal Cancer
  • Tucson, Arizona
  • +7 more
Jan 13, 2023

Rechallenge of BRAF +/- MEK Inhibitors FollowingAdverse Event in

Active, not recruiting
  • Cancer
  • BRAF inhibitor
  • (no location specified)
Oct 13, 2021

Advanced Cancer, Metastatic Cancer, Solid Tumor Trial in United States (JZP815)

Recruiting
  • Advanced Cancer
  • +2 more
  • Denver, Colorado
  • +4 more
Jan 10, 2023

Uveal Melanoma Trial in New York, Houston (Selumetinib)

Active, not recruiting
  • Uveal Melanoma
  • New York, New York
  • +2 more
Jun 28, 2022

Acute Myeloid Leukemia Trial in United States (ERAS-007, ERAS-601, Gilteritinib)

Withdrawn
  • Acute Myeloid Leukemia
  • San Francisco, California
  • +3 more
Jun 13, 2022

Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma Trial in Worldwide (Binimetinib Oral Tablet

Not yet recruiting
  • Adamantinous Craniopharyngioma
  • Recurrent Adamantinomatous Craniopharyngioma
  • Binimetinib Oral Tablet [Mektovi]
  • Aurora, Colorado
  • +17 more
Nov 28, 2022

Metastatic Melanoma, Unresectable Melanoma, Melanoma Trial (Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover

Not yet recruiting
  • Metastatic Melanoma
  • +2 more
  • Lifileucel plus Pembrolizumab
  • Pembrolizumab with Optional Crossover Period
  • (no location specified)
Feb 13, 2023

Low-grade Glioma, Plexiform Neurofibroma, CNS Glioma Trial in Canada (Trametinib)

Active, not recruiting
  • Low-grade Glioma
  • +2 more
  • Calgary, Alberta, Canada
  • +6 more
Oct 25, 2022

Arteriovenous Malformations Trial (Trametinib tablet)

Not yet recruiting
  • Arteriovenous Malformations
  • Trametinib tablet
  • (no location specified)
Oct 17, 2023

Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 Trial in United States (Selumetinib, Sirolimus)

Active, not recruiting
  • Malignant Peripheral Nerve Sheath Tumors
  • Neurofibromatosis 1
  • Washington, District of Columbia
  • +4 more
Apr 1, 2022

BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma

Active, not recruiting
  • Melanoma
  • Dabrafenib and Trametinib
  • Buxtehude, Niedersachsen, Germany
  • +35 more
Aug 25, 2022

Advanced Solid Tumors With MAPK Pathway Mutations Trial in Nedlands (D3S-002)

Not yet recruiting
  • Advanced Solid Tumors With MAPK Pathway Mutations
  • Nedlands, Western Australia, Australia
    D3 Bio Investigative Site
May 24, 2023

Tumors, Nerve Tissue, Neurofibromatosis 1, Heredodegenerative Disorders, Nervous System Trial (Selumetinib (AZD6244 hyd sulfate)

Withdrawn
  • Neoplasms, Nerve Tissue
  • +3 more
  • Selumetinib (AZD6244 hyd sulfate) 50mg/dose
  • Selumetinib (AZD6244 hyd sulfate) 25mg/m2
  • (no location specified)
Apr 3, 2019

Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) Trial run by the NCI (Selumetinib)

Active, not recruiting
  • Neurofibromatosis 1 (NF1)
  • Plexiform Neurofibromas (PN)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

Pancreatic Cancer, Adenocarcinoma Trial in Canada (GSK2256098, Trametinib)

Active, not recruiting
  • Pancreatic Cancer
  • Adenocarcinoma
  • Hamilton, Ontario, Canada
  • +3 more
May 12, 2022

Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1) Trial in United States (Mirdametinib (PD-0325901) oral capsule or

Active, not recruiting
  • Plexiform Neurofibroma
  • Neurofibromatosis Type 1 (NF1)
  • Mirdametinib (PD-0325901) oral capsule or dispersible tablet
  • Birmingham, Alabama
  • +49 more
Nov 17, 2022

Solid Tumor Trial in Toronto (Binimetinib, Encorafenib)

Recruiting
  • Solid Tumor
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Sep 23, 2022

Advanced Solid Tumor, Advanced or Metastatic NSCLC Trial in Guanzhou, Chengdu (BBP-398)

Recruiting
  • Advanced Solid Tumor
  • Advanced or Metastatic Non-small Cell Lung Cancer
  • Guanzhou, Guangdong, China
  • +1 more
Nov 30, 2022

Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease Trial in Memphis, Houston (Cobimetinib)

Recruiting
  • Langerhan's Cell Histiocytosis
  • +6 more
  • Phoenix, Arizona
  • +6 more
Jan 12, 2023

Advanced Solid Tumor (Phase 1), Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous) Trial in United States (IMM-1-104)

Recruiting
  • Advanced Solid Tumor (Phase 1)
  • +4 more
  • Duarte, California
  • +4 more
Feb 2, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Canada (Laboratory Biomarker Analysis, Pharmacological

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Laboratory Biomarker Analysis
  • +3 more
  • Calgary, Alberta, Canada
  • +4 more
Feb 10, 2022